Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7204239 plus tirzepatide for weight loss with muscle preservation in adults with overweight or obesity
2024-519561-22-00Phase 2Authorised
- Sponsor
- Roche
- Start
- Jul 2025
- Modality
- Recombinant Proteins and Enzymes, Peptides, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 2, randomised, double-blind trial in obesity and Overweight comparing RO7204239 + Mounjaro with RO7204239 placebo + Mounjaro (2 arms). Primary endpoint: Percent change in body weight from baseline at Week 48. Planned start Jul 2025; status: authorised.
02
Drugs
emugrobarttirzepatide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2024-519561-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519561-22-00.